■酪氨酸激酶抑制剂(TKIs)和免疫疗法代表转移性肾细胞癌(mRCC)患者的骨干治疗。本研究的目的是描述帕唑帕尼或卡博替尼治疗的mRCC患者的平均红细胞体积(MCV)和红细胞分布宽度(RDW)。并探讨它们对肿瘤结果的潜在影响。
我们于2012年1月至2020年12月在意大利9个中心对接受帕唑帕尼或卡博替尼治疗的mRCC患者进行了一项多中心回顾性观察性研究。描述性统计,单变量,并进行多变量分析。
■主要终点是贫血的发生率和随时间的趋势,巨细胞增多症(MCV升高),和红细胞增多症(RDW升高)。次要终点是MCV和RDW与客观反应率(ORR)的相关性,无进展生存期(PFS),总生存率(OS)。
■共纳入301例患者;平均Hb值为12.5g/dl,在第15天观察到平均增加1g/dl,并在3个月时维持。大多数患者有基线大红细胞增多症(MCV水平>87fl),治疗3个月后平均显着增加。在单因素分析中,巨细胞增多症患者的ORR较好,较长的PFS,和OS。约1/3的患者有基线红细胞增多症(RDW>16%),治疗3个月后平均显着增加。在单变量分析中,RDW值的患者有16%的ORR较高,较长的PFS,和OS。在多变量分析中,在接受帕唑帕尼治疗的患者中,基线巨细胞增多与较好的PFS显著相关,在所有患者中,基线巨细胞增多与较短的OS显著相关.
■接受帕唑帕尼或卡博替尼治疗的mRCC患者可能出现基线大细胞增多和异细胞增多。Hb显著增加,MCV,TKI开始后观察到RDW。在接受帕唑帕尼治疗的患者中,基线大细胞增多与PFS呈正相关,基线异细胞增多会影响接受TKIs治疗的患者的生存率。
UNASSIGNED: Tyrosine-kinase inhibitors (TKIs) and immunotherapy represent the backbone treatment for metastatic renal cell carcinoma (mRCC) patients. The aim of the present study was to describe mean corpuscular volume (MCV) and red cell distribution width (RDW) in mRCC patients treated with pazopanib or cabozantinib, and to explore their potential impact on oncological outcomes.
UNASSIGNED: We conducted a multicenter retrospective observational study in mRCC patients treated with pazopanib or cabozantinib between January 2012 and December 2020 in nine Italian centers. Descriptive statistics, univariate, and multivariate analyses were performed.
UNASSIGNED: The primary endpoints were the incidence and trend over time of anemia, macrocytosis (elevated MCV), and
anisocytosis (elevated RDW). The secondary endpoints were the correlations of MCV and RDW with objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).
UNASSIGNED: A total of 301 patients were enrolled; mean Hb value was 12.5 g/dl, a mean increase of 1 g/dl was observed at day 15 and maintained at 3 months. Most patients had baseline macrocytosis (MCV levels > 87 fl), with a significant mean increase after 3 months of treatment. At univariate analysis patients with macrocytosis had better ORR, longer PFS, and OS. About one third of patients had baseline
anisocytosis (RDW > 16%), with a significant mean increase after 3 months of treatment. At univariate analysis, patients with RDW values ⩽ 16% had higher ORR, longer PFS, and OS. At multivariate analysis, baseline macrocytosis was significantly associated with better PFS in patients treated with pazopanib and baseline
anisocytosis with shorter OS in all patients.
UNASSIGNED: mRCC patients treated with pazopanib or cabozantinib may have baseline macrocytosis and
anisocytosis. A significant increase of Hb, MCV, and RDW after TKIs start was observed. Baseline macrocytosis is positively correlated with PFS in patients treated with pazopanib and baseline
anisocytosis affects survival of patients treated with TKIs.